| Literature DB >> 31699117 |
Gaopeng Li1, Ting Liu2, Jian Zheng3, Wenqin Kang4, Jun Xu5, Zefeng Gao6, Jinfeng Ma7.
Abstract
BACKGROUND: Differentiation between pancreatic cancer (PC) and focal form of autoimmune pancreatitis (AIP) is very challenging, with similar clinical presentations, laboratory results and morphologic imagings of US, CT, EUS, MRI, ERCP, PET-CT. Even serum IgG4 and biopsy sometimes cannot give clear-cut differential accurate diagnostis. Considering the totally different management strategy of the two diseases, accurate diagnostic value is urgently needed to remind the clinicians of the rare diagnosis of untypical AIP among frequent PC-suspected patients.Entities:
Keywords: Autoimmune pancreatitis; Biopsy; IgG4; Pancreatic cancer
Year: 2019 PMID: 31699117 PMCID: PMC6839088 DOI: 10.1186/s13023-019-1217-z
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Changes of tumor markers in two cases
| Case 1 | Case 2 | Reference | |||||
|---|---|---|---|---|---|---|---|
| time | 27 days | 31 days | 37 days | 3 days | 15 days | 64 days | |
| CEA | 1.46 | 0.84 | 0.75 | 1.5 | 0.80 | 0.15 | <3 μ g/L |
| CA199 | 426.50↑ | 227.89↑ | 282.22↑ | 1.1 | 2.05 | 0.55 | <20 U/mL |
| CA242 | 43.34↑ | 40.92↑ | 1.03 | 1.65 | <12 U/mL | ||
| AFP | 2.92 | 4.35 | 4.16 | 6.0 | 5.17 | 6.15 | <15 μ g/L |
| CA724 | 4.25 | 1.55 | 0.82 | 0.66 | <10 U/mL | ||
| CA50 | 222.70↑ | 32.44 | 51.52 | 13.55 | <20 U/mL | ||
| SCC | 0.24 | 0.27 | 0.19 | <1 ng/mL | |||
| TPA | 5.25↑ | 9.28↑ | 14.63↑ | <2 ng/mL | |||
| TPS | 234.57↑ | 765.82↑ | 1010.07↑ | <150 U/L | |||
| VEGF | 300.00 | 257.66 | 617.26 | 62–707 pg/mL | |||
| CA125 | 28 | 5.75 | <35 U/mL | ||||
| CA153 | 7.5 | <31.3 U/mL | |||||
Serological immune realted antibody: ↑ represent higher than reference, ↓ represent lower than reference. Immunoturbidimetry (ITM), Western blotting (WB), indirect immunofluorescence (IFL), blank no test
| Case 1 (postoperative) | Case 2 | Reference (unit) | method | ||
|---|---|---|---|---|---|
| preoperative | postoperative | ||||
| IgA | 1.66 | 2.14 | 2.23 | 0.7–4.0 g/L | Elisa |
| IgG | 13.34 | 11.34 | 16.3 | 7–16 g/L | Elisa |
| IgM | 3.25↑ | 0.67 | 0.909 | 0.4–2.3 g/L | Elisa |
| IgE | 657.50↑ | 20~200 IU/mL | Elisa | ||
| t-PSA | 0.831 | 0–4 ng/mL | Elisa | ||
| f-PSA | 0.301 | 0–4 ng/mL | Elisa | ||
| ASO | < 25.0 | 0–116 IU/mL | Elisa | ||
| Anti-CCP | 1.75 | 0–25 IU/mL | Elisa | ||
| anti-TB | negative | negative | Elisa | ||
| AMA-M2 | 8.12 | 0–25 IU/mL | Elisa | ||
| Anti-a-Fodrin | negative | negative | Elisa | ||
| Complement 3 | 1.09 | 0.740↓ | 0.79–1.52 g/L | ITM | |
| Complement 4 | 0.14 | 0.069↓ | 0.1–0.4 g/L | ITM | |
| RF | 1.95 | 73.1↑ | <20 IU/mL | ITM | |
| IgG1 | 1170.0↑ | 405–1011 mg/dL | ITM | ||
| IgG2 | 234 | 169–768 mg/dL | ITM | ||
| IgG3 | 32.8 | 11–85 mg/dL | ITM | ||
| IgG4 | 5.43 | 98 | 266.0↑ | <201 mg/dL | ITM |
| ANA | negative | negative | negative | IFL | |
| AKA | negative | negative | IFL | ||
| ASMA | negative | negative | IFL | ||
| AMA | 1:100 ↑ | negative | IFL | ||
| AMA-M2 | negative | negative | negative | WB | |
| Sp100 | negative | negative | negative | WB | |
| LKM1 | negative | negative | negative | WB | |
| Gp210 | negative | negative | negative | WB | |
| LC1 | negative | negative | negative | WB | |
| SLA | negative | negative | negative | WB | |
| Anti-Nucleosomes | negative | negative | WB | ||
| Anti-dsDNA | negative | negative | WB | ||
| SmD1 | negative | negative | WB | ||
| Anti-PO | negative | negative | WB | ||
| Anti-Histones | negative | negative | WB | ||
| U1-SnRNP | negative | negative | WB | ||
| Anti-SSA/Ro60 | negative | negative | WB | ||
| Anti-SSA/Ro52 | negative | negative | WB | ||
| SSB/La | negative | negative | WB | ||
| Anti-Slc-70 | negative | negative | WB | ||
| Anti-CENP-B | negative | negative | WB | ||
| Anti-Jo-1 | negative | negative | WB | ||
Fig. 1Intermittent liver damage presentation of liver enzymes including, AST, ALT, ALP, GGT (a) and mild raised but fluctuating cholestasis of Tbil, Dbil, Ibil (b) for both AIP cases